
Claims

1. A compound of the formula I



in which

A is a 6 ~~to 10~~ membered aryl radical ~~or a 5 to 10 membered heteroaryl radical, where~~
~~the aryl and heteroaryl radical may be mono- or bicyclic,~~
~~and the heteroaryl radical may comprise one or more heteroatoms selected from the group of nitrogen, oxygen and sulfur;~~

where one or more hydrogen atoms in said ~~mono- or bicyclic~~ aryl ~~or heteroaryl~~ radical~~s~~ may be replaced by substituents R1 which are selected independently of one another from the group of F, Cl, Br, I, (C_1-C_{10})-alkyl-, (C_2-C_{10})-alkenyl-, (C_2-C_{10})-alkynyl-, (C_3-C_{14})-cycloalkyl-, (C_4-C_{20})-cycloalkylalkyl-, (C_4-C_{20})-cycloalkylalkyloxy-, (C_1-C_{10})-alkoxy-, (C_1-C_{10})-alkylthio-, (C_6-C_{14})-aryl-, (C_2-C_{13})-heteroaryl, -CN, -NR13R14, -C(O)R12, -SF_5, -$S(O)_n$R12, -C(O)OR12, -C(O)NR13R14 and -$S(O)_n$NR13R14;
~~where two adjacent radicals R1 may also form a saturated or partly unsaturated (C_5-C_{10})-cycloalkyl radical or a saturated or partly unsaturated (C_2-C_9)-cycloheteroalkyl radicals, where the cycloheteroalkyl radical may comprise 1, 2 or 3 nitrogen, 1 or 2 oxygen, 1 or 2 sulfur, 1 or 2 nitrogen and 1 oxygen or 1 sulfur atom;~~

where said alkyl, alkenyl, alkynyl, ~~cycloalkyl, cycloalkylalkyl, cycloalkylalkyloxy, cycloheteroalkyl,~~ alkoxy, and alkylthio radicals may be substituted independently of one another one or more times by F, OH or (C_1-C_{10})-alkoxy;

B is a mono- or fused bicyclic radical selected from the group
of 6 to 10 membered aryl radicals,
of 5 to 10 membered heteroaryl radicals,
of 3 to 10 membered cycloalkyl radicals,
of 9 to 14 membered cycloalkylaryl radicals,
of 8 to 14 membered cycloalkylheteroaryl radicals,
of 3 to 10 membered cycloheteroalkyl radicals,
of 9 to 14 membered cycloheteroalkylaryl radicals and
of 8 to 14 membered cycloheteroalkylheteroaryl radicals,

where the cycloalkyl or cycloheteroalkyl units may be saturated or partly unsaturated, and

where the heterocyclic groups may comprise one or more heteroatoms selected from the group of nitrogen, oxygen and sulfur;

where one or more hydrogen atoms in the radicals B may be replaced by substituents R5 which are selected independently of one another from the group of (C_1-C_{10})-alkyl radicals, of (C_2-C_{10})-alkenyl radicals, of (C_2-C_{10})-alkynyl radicals, of (C_1-C_{10})-alkoxy radicals, of (C_1-C_{10})-alkylthio radicals, of (C_3-C_{14})-cycloalkyl radicals, of (C_4-C_{20})-cycloalkylalkyl radicals, of (C_4-C_{20})-cycloalkylalkyloxy, of (C_2-C_{19})-cycloheteroalkyl radicals, of (C_3-C_{19})-cycloheteroalkylalkyl radicals, of (C_3-C_{11})-cycloalkyloxy radicals, of (C_2-C_{11})-cycloheteroalkyloxy radicals, of (C_6-C_{10})-aryl radicals, of (C_1-C_9)-heteroaryl radicals, of (C_9-C_{14})-cycloalkylaryl radicals, of (C_5-C_{13})-cycloalkylheteroaryl radicals, (C_7-C_{13})-cycloheteroalkylaryl radicals and (C_4-C_{12})-cycloheteroalkylheteroaryl radicals, where

R15 is a radical selected from the group of H, (C_1-C_{10})-alkyl, (C_2-C_{10})-alkenyl, (C_2-C_{10})-alkynyl, (C_3-C_{14})-cycloalkyl, (C_4-C_{20})-cycloalkylalkyl, (C_2-C_{13})-cycloheteroalkyl and (C_3-C_{19})-cycloheteroalkylalkyl, each of which may be substituted independently of one another one or more times by F, OH, CN or (C_1-C_{10})-alkoxy;

R19 is an H, a (C_1-C_{10})-alkyl radical or (C_1-C_{14})-cycloalkyl radical, COR12, -CO(NR13R14), $S(O)_nR12$ or $-S(O)_2NR13R14$, where the alkyl radical may be substituted independently of one another one or more times by R10;

and in which

n is 0, 1 or 2;

p is 1 ~~or 2~~ and

q is 0,

and the pharmaceutically acceptable salts thereof,

and in which

i) in the case where A is phenyl, B is phenyl or benzodioxolanyl and R3 and R4 are H, (C_1-C_{10})-alkyl, (C_3-C_{14})-cycloalkyl or (C_7-C_{20})-arylalkyl or R3 and R4 together are an unsubstituted pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl radical or 4-methylpiperazinyl radical, at least one R5 radical which is not a (C_1-C_{10})-alkyl, (C_1-C_{10})-alkoxy, OH, CF_3, F, Cl, Br or I radical must be present,

ii) in the case where A is phenyl and R3 and R4 are a (C_1-C_{10})-alkyl, (C_3-C_{14})-cycloalkyl or a (C_4-C_{20})-cycloalkylalkyl radical, at least one R5 radical which is not an F, Cl, Br, I, (C_1-C_4)-alkyl, (C_1-C_4)-alkoxy, CF_3, OCF_3, CN, NO_2, NH_2, -NH((C_1-C_{10})-alkyl), -N((C_1-C_{10})-alkyl)$_2$, unsubstituted or substituted benzoyl or an unsubstituted or substituted phenyl-$(CH_2)_r$-Y-$(CH_2)_s$- radical, with Y being a bond or an oxygen and r and s being 0 to 4, where r+s is not greater than 4, must be present.

2. A compound as claimed in claim 1 with formula Ic

R2 is absent or is one or more substituents which may be selected independently of one another from the group of F and of (C_1-C_6)-alkyl radicals, where the alkyl radicals may be substituted independently of one another one or more times by F,

where the radicals A, X, L, q, R1, R3, R4 and R5 have the meaning stated in claim 1, and the pharmaceutically acceptable salts thereof.

3. A compound as claimed in claim 1 or 2, where

A is a phenyl ~~or a 5 to 6 membered heteroaryl radical, where the heteroaryl radical may comprise as heteroatoms 1, 2 or 3 nitrogen atoms, 1 oxygen atom, 1 sulfur atom, 1 or 2 nitrogen and 1 oxygen or 1 sulfur atom, where one or more hydrogen atoms in the phenyl or heteroaryl radical may be replaced independently of one another by a radical R1~~;

B is a 6 to 10 membered monocyclic or fused bicyclic aryl group, a 5 to 10 membered monocyclic or fused bicyclic heteroaryl group, a 9 to 14 membered fused bicyclic cycloalkylaryl group, an 8 to 14 membered fused bicyclic cycloalkylheteroaryl group, a fused 9 to 14 membered bicyclic cycloheteroalkylaryl group or an 8 to 14 membered fused bicyclic cycloheteroalkylheteroaryl group, each of which may be substituted independently of one another one or more times by R5,

where the cycloalkyl and cycloheteroalkyl units may be saturated or partly unsaturated, and

where the cycloheteroalkylaryl groups may comprise as heteroatoms 1 nitrogen atom, 1 or 2 oxygen atoms, 1 or 2 sulfur atoms, 1 nitrogen atom and 1 oxygen or 1 sulfur atom or 1 oxygen and 1 sulfur atom,

of OH, (=O), F, Cl, Br, CN, NO_2, -NR13R14, -NR13COR12, -NR13COOR12, -NR12CONR13R14, -NR13-$S(O)_2$-R12, -NR13-$S(O)_2$-NR13R14, -COOR12, -COR12; -CO(NR13R14), -$S(O)_n$R12 and -$S(O)_2$NR13R14,

where R12, R13 and R14 are independently of one another H or (C_1-C_4)-alkyl,

or

R3 and R4 form together with the nitrogen to which they are bonded a 4-8 membered, saturated, unsaturated or partly unsaturated heterocycle which may additionally comprise one or more heteroatoms from the list –O-, -$S(O)_n$-, with n = 0, 1 or 2, =N- and -NR8-, where

the heterocyclic radicals may be substituted independently of one another one or more times by a radical selected from the group of radicals R7 and R9,

where the heterocyclic radicals may be bridged by a bond, (C_1-C_7)-alkyl, (C_1-C_6)-saturated or unsaturated heteroalkyl chains or by –NH- or -N(C_1-C_4)-alkyl-, and where the alkyl and heteroalkyl chains may also form a spirocyclic ring system with the ring system formed by R3 and R4,

and where R8 in the group NR8 may form with the ring which the radicals R3 and R4 may form a further saturated, unsaturated or partly unsaturated heterocycle which may additionally comprise one or two heteroatoms from the list –O-, -$S(O)_n$-, with n = 0, 1 or 2, =N- and –NR19-, with R19 equal to H or (C_1-C_4)-alkyl;

where the radicals R7, R8 and R9 have the meaning stated in claim 1, and the pharmaceutically acceptable salts thereof.

5. A compound as claimed in any of claims 1, 2, 3 or 4, where

R3 and R4 form together with the nitrogen to which they are bonded a 4-8 membered, saturated, unsaturated or partly unsaturated heterocycle which may additionally comprise one or more heteroatoms from the list –O-, -$S(O)_n$-, with n = 0, 1 or 2, =N- and -NR8-, where

the heterocyclic radicals may be substituted independently of one another one or more times by a radical selected from the group of radicals R7 and R9,
where the heterocyclic radicals may be bridged by a bond, $(C_1$-$C_7)$-alkyl, $(C_1$-$C_6)$-saturated or unsaturated heteroalkyl chains or by –NH- or -N$(C_1$-$C_4)$-alkyl-, and where the alkyl and heteroalkyl chains may also form a spirocyclic ring system with the ring system formed by R3 and R4,
and where R8 in the group NR8 may form with the ring which the radicals R3 and R4 may form a further saturated, unsaturated or partly unsaturated heterocycle which may additionally comprise one or two heteroatoms from the list –O-, -$S(O)_n$-, with n = 0, 1 or 2, =N- and –NR19-, with R19 equal to H or $(C_1$-$C_4)$-alkyl;

where the radicals R7, R8 and R9 have the meaning stated in claim 1, and the pharmaceutically acceptable salts thereof.


~~56~~. A compound as claimed in any of claims 1, 2, 3 or 4, where

B is a phenyl group, a naphthyl group, a pyridinyl group, a quinolinyl group, an isoquinolinyl group, an indolyl group, a benzothiophenyl group, a benzodihydrothiophenyl group, a benzofuranyl group, a

where R12, R13 and R14 are independently of one another a hydrogen radical or a radical selected from the group of unsubstituted or substituted (C1-C4)-alkyl radicals, where the substituents of the alkyl radicals are selected from F, OH, (=O), NH_2, $NH(C_1\text{-}C_4)$alkyl, $N((C_1\text{-}C_4)alkyl)_2$, CN and $(C_1\text{-}C_{10})$-alkoxy;

and the pharmaceutically acceptable salts thereof.

67. A compound as claimed in claim 1 with formula Ia



Ia,

where

A is a phenyl or 5 to 6 membered heteroaryl radical, where the heteroaryl radical may comprise as heteroatoms 1, 2 or 3 nitrogen atoms, 1 oxygen atom, 1 sulfur atom, 1 or 2 nitrogen and 1 oxygen or 1 sulfur atom, where one or more hydrogen atoms in said phenyl or heteroaryl radical may be replaced independently of one another by a radical R1;

B is a 6 to 10 membered monocyclic or fused bicyclic aryl group, a 5 to 10 membered monocyclic or fused bicyclic heteroaryl group, a 9 to 14 membered fused bicyclic cycloalkylaryl group, an 8 to 14 membered fused bicyclic cycloalkylheteroaryl group, a 9 to 14 membered fused bicyclic cycloheteroalkylaryl group or an 8 to 14 membered fused

bicyclic cycloheteroalkylheteroaryl group, each of which may be substituted independently of one another one or more times by R5

where the cycloalkyl and cycloheteroalkyl units may be saturated or partly unsaturated, and

where the cycloheteroalkylaryl groups may comprise as heteroatoms 1 or 2 nitrogen atoms, 1 or 2 oxygen atoms, 1 or 2 sulfur atoms, 1 nitrogen atom and 1 oxygen or 1 sulfur atom or 1 oxygen and 1 sulfur atom,

and the heteroaryl and cycloalkylheteroaryl groups may comprise 1, 2, 3 or 4 nitrogen atoms, 1 oxygen atom, 1 sulfur atom, 1 or 2 nitrogen atoms and 1 oxygen or sulfur atom or 1 oxygen and 1 sulfur atom,

and the cycloheteroalkylheteroaryl group may comprise as heteroatoms 1, 2, 3 or 4 nitrogen atoms, 1 or 2 oxygen atoms, 1 or 2 sulfur atoms, 1, 2 or 3 nitrogen atom and 1 oxygen or 1 sulfur atom or 1 oxygen and 1 sulfur atom;

R2 is absent or is one or more substituents which may be selected independently of one another from the group of F and of (C_1-C_6)-alkyl radicals, where the alkyl radicals may be substituted independently of one another one or more times by F;

where the radicals X, L, q, R1, R3, R4 and R5 have the meaning stated in claim 1, and the pharmaceutically acceptable salts thereof.

~~7~~8. A compound as claimed in claim 1 with formula Ib

and where R8 may form with the ring which the radicals R3 and R4 may form a further saturated, unsaturated or partly unsaturated heterocycle which may additionally comprise one or two heteroatoms from the list –O-, -$S(O)_n$-, with n = 0, 1 or 2, =N-, -NH- and –N((C_1-C_4)-alkyl);

where R7, R8 and R9 have the meaning indicated in claim 1, and the pharmaceutically acceptable salts thereof.

~~8~~9. A compound as claimed in any of claims 1, 2, 3, ~~4, 5 or~~ 6 or 7, where

R3 and R4 form together with the nitrogen to which they are bonded a 4-10 membered, saturated, unsaturated or partly unsaturated heterocycle which may additionally comprise one or more heteroatoms from the list –O-, -$S(O)_n$-, =N- and –NR8-, where

the heterocyclic radicals may be substituted independently of one another one or more times by radicals selected from the group of R7 and R9, and where

the heterocyclic radicals formed by R3 and R4 may be bridged by a bond, by a saturated or unsaturated (C_1-C_{10})-alkyl or (C_1-C_9)-heteroalkyl chain or by –NR15-, -O- or -S-, and where

the alkyl and heteroalkyl chains may also form a spirocyclic ring system with the ring system formed by R3 and R4, where the alkyl and heteroalkyl bridges may be substituted independently of one another one or more times by radicals selected from the group of R7 and R9,

and where

R8 in the group -NR8- may form with the ring which R3 and R4 may form a further saturated, unsaturated or partly unsaturated heterocycle which may be substituted independently of one another one or more times by radicals selected from the group of R7 and R9, and may additionally comprise one or more heteroatoms from the list –O-, -$S(O)_n$-, -N= and -NR19-;

where n, R7, R8, R9 and R19 have the meaning indicated in claim 1, and the pharmaceutically acceptable salts thereof.

~~9~~10. A compound as claimed in any of claims 1, 2, 3, 4, 5, 6, 7 or 8 or 9, where

R3 and R4 form together with the nitrogen to which they are bonded a 4-8 membered, saturated, unsaturated or partly unsaturated heterocycle which may additionally comprise one or more heteroatoms from the list –O-, -$S(O)_n$-, with n = 0, 1 or 2, =N- and –NR8-, where

the heterocyclic radicals may be substituted independently of one another one or more times by radicals selected from the group of radicals R7 and R9,

and where R8 may form with the ring which the radicals R3 and R4 form may form together with an adjacent C atom a fused triazole or pyrrolidine ring;

where R7, R8 and R9 have the meaning indicated in claim 1, and the pharmaceutically acceptable salts thereof.

~~10~~11. A compound as claimed in any of claims 1, 2, 3, 4, ~~5, 6, or 7~~ 5, 6, or 7 or 8, where

R3 and R4 are independently of one another a hydrogen radical or a radical which is selected from the group of (C_1-C_{10})-alkyl radicals, of (C_2-C_{10})-alkenyl radicals, of (C_2-C_{10})-alkynyl radicals, of (C_3-C_{14})-cycloalkyl radicals, of (C_4-C_{20})-cycloalkylalkyl radicals, of (C_2-C_{19})-cycloheteroalkyl radicals, of (C_3-C_{19})-cycloheteroalkylalkyl radicals, of (C_6-C_{10})-aryl radicals, of (C_7-C_{20})-arylalkyl radicals, of (C_1-C_9)-heteroaryl radicals and of (C_2-C_{19})-heteroarylalkyl radicals, where

the radicals R3 and R4 may be substituted independently of one another one or more times by a radical from the group of OH, NH_2, (=O), F, Cl, Br, I, CN, NO_2, -NR13R14, -NR13COR12, -NR13COOR12, -NR12CONR13R14, -NR13-$S(O)_2$-R12, -NR13-

$S(O)_2$-NR13R14, -COOR12, -COR12; -CO(NR13R14), $S(O)_n$R12 and -$S(O)_2$R13R14;

where R12, R13 and R14 have the meaning indicated in claim 1, and the pharmaceutically acceptable salts thereof.

~~11. A compound of the formula I as claimed in claim 1, wherein the compound is selected from the group consisting of:~~

~~(R)-1-[rac-trans-(1,2)-1-(1H-benzotriazol-4-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;~~

~~(R)-1-[rac-trans-(1,2)-1-(2,4-difluorophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;~~

~~(R)-1-[rac-trans-(1,2)-1-(2,6-dimethoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;~~

~~(R)-1-[rac-trans-(1,2)-1-(2-bromo-4-methylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;~~

~~(R)-1-[rac-trans-(1,2)-1-(2-bromophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;~~

~~(R)-1-[rac-trans-(1,2)-1-(2-chloro-4-methylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;~~

~~(R)-1-[rac-trans-(1,2)-1-(2-chloro-6-methylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;~~

~~(R)-1-[rac-trans-(1,2)-1-(2-chloropyridin-4-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;~~

~~(R)-1-[rac-trans-(1,2)-1-(2-chloroquinolin-8-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;~~

~~(R)-1-[rac-trans-(1,2)-1-(2-fluoro-4-methoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;~~

~~(R)-1-[rac-trans-(1,2)-1-(2-fluoro-5-methylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;~~

~~(R)-1-[rac-trans-(1,2)-1-(2-fluoro-6-methoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;~~

(R)-1-[rac-trans-(1,2)-1-(2-methanesulfonylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(2-methoxy-5-methylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(2-morpholin-4-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(2-trifluoromethoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(3,4-difluorophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(3-chloro-4-fluorophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(3-chloro-4-methylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(3-chloro-5-methoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(3-chlorophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(3-difluoromethoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(3-fluorophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(3-tetrazol-1-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(4-[1,2,4]triazol-1-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(4-bromo-3-methoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(4-chloro-2-methoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(4-chloro-3-methylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(R)-1-[rac-trans-(1,2)-1-(4-chlorophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(4-dimethylaminomethylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(4-fluoro-2-isoxazol-5-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(4-fluoro-3-trifluoromethylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(4-fluorophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(4-imidazol-1-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(4-methanesulfonylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(4-methylsulfanylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(4-piperazin-1-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(4-trifluoromethylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(5,7-dimethylquinolin-8-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(5-fluoroquinolin-8-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(6-aminonaphthalen-1-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(6-chloropyridin-3-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(isoquinolin-7-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-1-(quinolin-3-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(R)-1-[rac-trans-(1,2)-1-(quinolin-5-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(R)-1-{rac-trans-(1,2)-1-[4-(2-methoxyethyl)phenoxy]-1,2,3,4-tetrahydronaphthalen-2-yl}piperidin-3-ylamine;

(R)-1-{rac-trans-(1,2)-1-[4-bromo-2-(1H-pyrazol-3-yl)phenoxy]-1,2,3,4-tetrahydronaphthalen-2-yl}piperidin-3-ylamine;

(R)-1-{rac-trans-(1,2)-1-[4-chloro-2-(1H-pyrazol-3-yl)phenoxy]-1,2,3,4-tetrahydronaphthalen-2-yl}piperidin-3-ylamine;

(R)-1-{rac-trans-(1,2)-1-[4-fluoro-2-(1H-pyrazol-3-yl)phenoxy]-1,2,3,4-tetrahydronaphthalen-2-yl}piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(1H-benzotriazol-4-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(1H-indol-6-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(2,4-difluorophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(2-bromo-4-methylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(2-bromophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(2-chloro-4-methylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(2-chloropyridin-4-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(2-chloroquinolin-8-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(2-fluoro-5-methylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(2-methanesulfonylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(2-methoxy-5-methylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(2-morpholin-4-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(2-trifluoromethoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(3-chloro-2-methylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(3-chloro-4-methylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(3-chloro-5-fluorophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(3-chloro-5-methoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(3-chlorophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(3-difluoromethoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(3-fluorophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(4-[1,2,4]triazol-1-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(4-bromo-3-methoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(4-chloro-2-methoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(4-chlorophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(4-difluoromethoxyphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(4-dimethylaminomethylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(4-fluoro-2-isoxazol-5-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;

(S)-1-[rac-trans-(1,2)-1-(4-fluorophenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(S)-1-[rac-trans-(1,2)-1-(4-imidazol-1-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(S)-1-[rac-trans-(1,2)-1-(4-methanesulfonylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(S)-1-[rac-trans-(1,2)-1-(4-methylsulfanylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(S)-1-[rac-trans-(1,2)-1-(4-piperazin-1-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(S)-1-[rac-trans-(1,2)-1-(4-trifluoromethylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(S)-1-[rac-trans-(1,2)-1-(5,7-dimethylquinolin-8-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(S)-1-[rac-trans-(1,2)-1-(5-fluoroquinolin-8-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(S)-1-[rac-trans-(1,2)-1-(6-aminonaphthalen-1-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(S)-1-[rac-trans-(1,2)-1-(6-chloropyridin-3-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(S)-1-[rac-trans-(1,2)-1-(pyridin-4-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(S)-1-[rac-trans-(1,2)-1-(quinolin-3-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(S)-1-[rac-trans-(1,2)-1-(quinolin-5-yloxy)-1,2,3,4-tetrahydronaphthalen-2-yl]piperidin-3-ylamine;
(S)-1-{rac-trans-(1,2)-1-[3-(2-aminoethyl)-1H-indol-5-yloxy]-1,2,3,4-tetrahydronaphthalen-2-yl}piperidin-3-ylamine;
(S)-1-{rac-trans-(1,2)-1-[4-(2-methoxyethyl)phenoxy]-1,2,3,4-tetrahydronaphthalen-2-yl}piperidin-3-ylamine;
(S)-1-{rac-trans-(1,2)-1-[4-bromo-2-(1H-pyrazol-3-yl)phenoxy]-1,2,3,4-tetrahydronaphthalen-2-yl}piperidin-3-ylamine;

(S)-1-{rac-trans-(1,2)-1-[4-fluoro-2-(1H-pyrazol-3-yl)phenoxy]-1,2,3,4-tetrahydronaphthalen-2-yl}piperidin-3-ylamine;

[3-methoxy-2-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)phenyl]acetonitrile;

{2-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-3-methoxyphenyl}acetonitrile;

{3-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}acetonitrile;

{4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}carbamic acid benzyl ester;

{4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}carbamic acid benzyl ester;

1-[1,3-dichloro-4-(4-methanesulfonylphenoxy)-4,5,6,7-tetrahydrobenzo[c]thiophen-5-yl]pyrrolidine;

1-{4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}pyrrolidine-2,5-dione;

1-{4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-3,5-difluorophenyl}propan-1-one;

1-{4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}pyrrolidine-2,5-dione;

2-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-5-chlorobenzamide;

2-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-5-chlorobenzonitrile;

2-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-6-fluorobenzonitrile;

2-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]benzamide;

2-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-5-bromobenzonitrile;

2-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-5-chlorobenzamide;

2-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-5-chlorobenzonitrile;

2-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-6-fluorobenzonitrile;

2-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]benzamide;

2-{4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}-N,N-dimethylacetamide;

2-{4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}-N,N-dimethylacetamide;

2-chloro-8-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)quinoline;

2-Fluoro-4-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)benzonitrile;

2-methyl-4-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)-1H-indole;

3-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)quinoline;

3-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]benzamide;

4-[4-((4S,5S)-1,3-dichloro-5-pyrrolidin-1-yl-4,5,6,7-tetrahydrobenzo[c]thiophen-4-yloxy)-3-fluorophenyl]-3,5-dimethyl-4H-[1,2,4]triazole;

4-[4-(1,3-dichloro-5-pyrrolidin-1-yl-4,5,6,7-tetrahydrobenzo[c]thiophen-4-yloxy)phenyl]-3,5-dimethyl-4H-[1,2,4]triazole;

4-[rac-trans-(1,2)-1-(2-methanesulfonylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]morpholine;

4-[rac-trans-(1,2)-1-(4-fluoro-2-isoxazol-5-ylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]morpholine;

4-[rac-trans-(1,2)-1-(4-methanesulfonylphenoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]morpholine;

4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-2,3-difluorobenzonitrile;

4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-2-fluorobenzonitrile;

4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-3,5-dimethylbenzonitrile;

4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-3-chloro-5-methoxy-benzonitrile;

4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-3-chlorobenzoic acid methyl ester;

4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-3-chlorobenzonitrile;

4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-3-fluorobenzonitrile;

4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]benzonitrile;

4'-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]biphenyl-4-carbonitrile;

4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-2,3-difluorobenzonitrile;

4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-2-chlorobenzonitrile;

4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-2-fluorobenzonitrile;

4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-3-chlorobenzoic acid methyl ester;

4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-3-chlorobenzonitrile;

4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-3-fluorobenzonitrile;

4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-3-nitrobenzonitrile;

4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]benzonitrile;

5-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)-naphthalen-2-ylamine;

5-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)quinoline;

~~5,7-dimethyl-8-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)quinoline;~~

~~5-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]benzo[1,3]oxathiol-2-one;~~

~~5-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]benzo[1,3]oxathiol-2-one;~~

~~5-{4-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}oxazole-4-carboxylic acid ethyl ester;~~

~~5-{4-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}oxazole-4-carboxylic acid ethyl ester;~~

~~5-chloro-2-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)benzonitrile;~~

~~5-fluoro-8-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)quinoline;~~

~~7-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)-isoquinoline;~~

~~8-(rac-trans-(1,2)-2-morpholin-4-yl-1,2,3,4-tetrahydronaphthalen-1-yloxy)quinoline-2-carbonitrile;~~

~~8-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]quinoline-2-carbonitrile;~~

~~N-{3-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-4-propylphenyl}acetamide;~~

~~N-{3-[rac-trans-(1,2)-2-((R)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}acetamide;~~

~~N-{3-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]-4-propylphenyl}acetamide;~~

~~N-{3-[rac-trans-(1,2)-2-((S)-3-aminopiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yloxy]phenyl}acetamide;~~

~~and the pharmaceutically acceptable salts thereof.~~

12. A compound of the formula I as claimed in claim 1, wherein the compound is selected from the group consisting of:

4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-benzenesulfonamide;
(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(morpholine-4-sulfonyl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;
1-{5-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-2-fluoro-phenyl}-3-methyl-1,3-dihydro-imidazol-2-one;

and the pharmaceutically acceptable salts thereof.


14. A compound of the formula I as claimed in claim 56, wherein the compound is selected from the group consisting of:

3-[trans-(1S,2S)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]-3,8-diazabicyclo[3.2.1]octane;
2-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]octahydropyrrolo[3,4-c]pyrrole;
2-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-5-methyloctahydropyrrolo[3,4-c]pyrrole;
(3R,5S)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-methanesulfonylphenoxy)indan-2-yl]-3,5-dimethylpiperazine;
(R)-1-[(1S,2S)-4,6-difluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]pyrrolidin-3-ol;
(R)-1-[rac-trans-(1,2)-4-chloro-6-fluoro-1-(3-methyl-4-trifluoromethanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-4-chloro-6-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-6-chloro-4-fluoro-1-(3-methyl-4-trifluoromethanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;
(R)-1-[rac-trans-(1,2)-6-chloro-4-fluoro-1-(4-methanesulfonylphenoxy)indan-2-yl]piperidin-3-ylamine;
(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(2-methylbenzothiazol-5-yloxy)indan-2-yl]pyrrolidin-3-ol;
(R)-1-[trans-(1S,2S)-4,6-dichloro-1-(4-[1,2,4]triazol-1-ylphenoxy)indan-2-yl]piperidin-3-ylamine;

4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-3-fluoro-benzenesulfonamide;
(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(4-methyl-piperazine-1-sulfonyl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;
4-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-benzenesulfonamide;
(R)-1-{trans-(1S,2S)-4,6-Dichloro-1-[4-(morpholine-4-sulfonyl)-phenoxy]-indan-2-yl}-pyrrolidin-3-ol;
1-{5-[trans-(1S,2S)-4,6-Dichloro-2-((R)-3-hydroxy-pyrrolidin-1-yl)-indan-1-yloxy]-2-fluoro-phenyl}-3-methyl-1,3-dihydro-imidazol-2-one;

and the pharmaceutically acceptable salts thereof.

15. A compound of the formula I as claimed in any of claims 1 to 14 and the pharmaceutically acceptable salts thereof, wherein the radical XLBR5 bonded at position 1 is directed downwards and the radical $-(CH_2)_qNR3R4$ bonded at position 2 is directed upwards, with the direction being determined starting from a plane which is spanned by the three carbon atoms in positions 1, 2 and 3, and the compounds are oriented as in formula Ie



Ie.

16. A compound of the formula I and/or the pharmaceutically acceptable salts thereof as claimed in one or more of claims 1 to 15 for use as a medicament.

~~17. The use of a compound as claimed in any of claims 1 to 15 and/or the pharmaceutically acceptable salts thereof for the manufactore of a medicament for~~

~~the treatment or prophylaxis of disorders through complete or partial inhibition of the Na^+/H^+ exchange by NHE3.~~

~~18~~17. ~~The u~~Use of a compound of the formula I and/or its pharmaceutically acceptable salts as claimed in one or more of claims 1 to 15 for the manufacture of a medicament for the treatment or prophylaxis of impairments of respiratory drive, of respiratory disorders, sleep-related respiratory disorders, sleep apneas, of snoring, of cystic fibrosis, of upper and lower airway diseases that are associated with viscous mucus, of acute and chronic renal disorders, of acute renal failure and of chronic renal failure, of impairments of bowel function, of constipation, of impairments of bilary function, of high blood pressure, of essential hypertension, of cardiovascular disorders, of diabetes mellitus, of the metabolic syndrome and of hyperlipidemias.

~~19~~18. ~~The u~~Use of a compound of the formula I and/or its pharmaceutically acceptable salts as claimed in one or more of claims 1 to 15 in combination with other pharmaceuticals or active ingredients for the manufacture of a medicament for the treatment or prophylaxis of impairments of respiratory drive, of respiratory disorders, sleep-related respiratory disorders, sleep apneas, of snoring, of cystic fibrosis, of upper and lower airway diseases that are associated with viscous mucus, of acute and chronic renal disorders, of acute renal failure and of chronic renal failure, of impairments of bowel function, of constipation, of impairments of bilary function, of high blood pressure, of essential hypertension, of cardiovascular disorders, of diabetes mellitus, of the metabolic syndrome and of hyperlipidemias.

~~20~~19. Use of ~~A~~a compound of the formula I and/or the pharmaceutically acceptable salts thereof as claimed in one or more of claims 1 to 15 alone or in combination with other pharmaceuticals or active ingredients for the manufacture of a medicament for the ~~for use in the~~ treatment or prophylaxis of impairments of the respiratory drive and/or of sleep-related respiratory impairments.

~~21~~20. Use of ~~A~~a compound of the formula I and/or the pharmaceutically acceptable salts thereof as claimed in one or more of claims 1 to 15 alone or in combination with other

pharmaceuticals or active ingredients for the manufacture of a medicament for the ~~for use in the~~ treatment or prophylaxis of sleep apneas.

~~22~~21. Use of a~~A~~ compound of the formula I and/or the pharmaceutically acceptable salts thereof as claimed in one or more of claims 1 to 15 alone or in combination with other pharmaceuticals or active ingredients for the manufacture of a medicament for the ~~for use in the~~ treatment or prophylaxis of snoring.

~~23~~22. Use of a~~A~~ compound of the formula I and/or the pharmaceutically acceptable salts thereof as claimed in one or more of claims 1 to 15 alone or in combination with other pharmaceuticals or active ingredients for the manufacture of a medicament for the ~~for use in the~~ treatment of cystic fibrosis.

~~24~~23. Use of a~~A~~ compound of the formula I and/or the pharmaceutically acceptable salts thereof as claimed in one or more of claims 1 to 15 alone or in combination with other pharmaceuticals or active ingredients for the manufacture of a medicament for the ~~for use in the~~ mucolytic treatment of upper and lower airway diseases that are associated with viscous mucus.

~~25~~24. A pharmaceutical preparation for human, veterinary or phytoprotective use comprising an effective amount of a compound of the formula I and/or of a pharmaceutically acceptable salt thereof as claimed in one or more of claims 1 to 15.

~~26~~25. A pharmaceutical preparation for human, veterinary or phytoprotective use comprising an effective amount of a compound of the formula I and/or of a pharmaceutically acceptable salt thereof as claimed in one or more of claims 1 to 15, in combination with other pharmacological active ingredients or pharmaceuticals.

~~27. A solvate or crystal modification of a compound of the formula I as claimed in any of claims 1 to 15, and the pharmaceutically acceptable salts thereof.~~